Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) – Cantor Fitzgerald issued their FY2016 earnings per share (EPS) estimates for Corbus Pharmaceuticals Holdings in a note issued to investors on Monday. Cantor Fitzgerald analyst E. Piros forecasts that the firm will post earnings per share of ($0.39) for the year. Cantor Fitzgerald has a “Buy” rating and a $17.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Corbus Pharmaceuticals Holdings’ FY2017 earnings at ($0.48) EPS.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.03. Corbus Pharmaceuticals Holdings had a negative net margin of 890.44% and a negative return on equity of 107.10%.
Separately, Aegis set a $12.00 price target on shares of Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a research report on Monday, September 19th.
Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) opened at 9.34 on Wednesday. Corbus Pharmaceuticals Holdings has a 12-month low of $1.01 and a 12-month high of $10.78. The company has a 50-day moving average of $6.53 and a 200 day moving average of $3.68. The firm’s market capitalization is $408.61 million.
In other Corbus Pharmaceuticals Holdings news, CFO Sean F. Moran acquired 148,960 shares of the business’s stock in a transaction that occurred on Thursday, August 18th. The shares were purchased at an average price of $3.32 per share, with a total value of $494,547.20. Following the completion of the transaction, the chief financial officer now owns 216,410 shares in the company, valued at $718,481.20. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Sean F. Moran acquired 17,900 shares of the business’s stock in a transaction that occurred on Friday, August 26th. The shares were acquired at an average cost of $3.92 per share, for a total transaction of $70,168.00. Following the transaction, the chief financial officer now owns 299,310 shares of the company’s stock, valued at approximately $1,173,295.20. The disclosure for this purchase can be found here. Corporate insiders own 11.60% of the company’s stock.
About Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.
Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.